Evidence is mounting that new therapies already used to treat gut diseases, type 2 diabetes, and obesity may help people with alcohol use disorder (AUD).
Researchers explore the therapeutic potential and clinical insights of GP1-RAs in the management of metabolic ...
Altimmune is redefining success in both obesity and MASH to position Pemvidutide in blue ocean categories. Read why I rate ...
5h
The secret agent in the decrease might be semaglutide, a GLP-1 receptor agonist that fuels popular weight loss drugs like ...
Health and Me on MSN6h
US For The First Time Sees A Drop In Obesity RatesA new study reveals a slight drop in U.S. obesity rates, driven by weight loss drugs, lifestyle changes post-COVID, and ...
FTC approves Novo Holdings' $16.5B Catalent acquisition. Deal includes selling 3 facilities to Novo Nordisk for $11B, despite ...
New research shows how weight loss meds like Wegovy are reshaping alcohol habits, offering new insights into addiction ...
For the first time in over a decade, obesity rates in the United States may finally be heading in the right direction and new weight loss drugs like semaglutide could be part of the reason why.
Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) have competed for decades. In recent years, these two healthcare leaders ...
It's been a good year for the stock market as a whole and a tremendous year for a couple of drugmaker start-ups. BTIG analyst ...
"Prescription drugs such as slimming injections have risks and side effects that must not be ignored," warned the Federal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback